Lb Pharmaceuticals (LBRX) Retained Earnings (2024 - 2026)

Lb Pharmaceuticals' Retained Earnings history runs 3 years deep, the most recent figure standing at -$148.6 million for Q1 2026.

• In Q1 2026, Retained Earnings changed N/A year-over-year to -$148.6 million; the TTM figure through Mar 2026 stood at -$148.6 million (changed N/A YoY), while the FY2025 annual figure was -$129.5 million, down 116791.89% from the prior year.
• Retained Earnings for Q1 2026 stood at -$148.6 million, down from -$129.5 million in the prior quarter.
• The five-year high for Retained Earnings was $111000.0 in Q4 2024, with the low at -$148.6 million in Q1 2026.
• The 3-year median for Retained Earnings is -$123.8 million (2025), against an average of -$99.0 million.
• Peak annual rise in Retained Earnings reached 116791.89% in 2025, while the deepest fall reached 116791.89% in 2025.
• Lb Pharmaceuticals' Retained Earnings stood at $111000.0 in 2024, then plunged by 116791.89% to -$129.5 million in 2025, then retreated by 14.72% to -$148.6 million in 2026.
• Business Quant data shows LBRX's Retained Earnings at -$148.6 million in Q1 2026, -$129.5 million in Q4 2025, and -$118.1 million in Q3 2025.